Drug Combination
Researchers confirm dosing, efficacy of pediatric HIV drug combination
Researchers confirmed the dosing of an ART combination designed to treat children with HIV and found that it was safe, well tolerated and efficacious through 24 weeks, according to results published in The Lancet HIV.
Obstructive sleep apnea combination drug safe, reduces disorder severity over 1 month
A combination of atomoxetine and oxybutynin taken for 30 days lowered baseline obstructive sleep apnea severity, according to results published in Annals of the American Thoracic Society.
Top news of May: Obstructive sleep apnea drug combination, central sleep apnea mortality
Healio has compiled the most-read news in pulmonology posted in May.
Oral combination obstructive sleep apnea drug lowers disorder severity over 1 month
WASHINGTON — A combination of atomoxetine and aroxybutynin taken for 4 weeks lessened obstructive sleep apnea severity, according to an abstract presented at the American Thoracic Society International Conference.
Axsome’s oral drug combination delays relapse of depression in phase 2 trial
Q&A: Longest survival among HCC patients seen with ‘breakthrough’ drug combination
In an exclusive interview with Healio Gastroenterology, Richard Finn, MD, discussed the results from a recent study of patients with hepatocellular carcinoma treated with combination therapy comprising atezolizumab, an immunotherapy drug and monoclonal antibody, and bevacizumab, another monoclonal antibody against the vascular endothelial growth factor (VEGF).
Q&A: Additional therapies for secondary prevention may be effective, but also expensive
Results of a 5-year estimate showed that up to 20% of CV events could be prevented if patients with ischemic heart disease or MI received additional secondary prevention therapies that they are eligible for.